Neoadjuvant and Adjuvant Therapies in Prostate Cancer

Urologic Clinics of North America

Volumn 37, Issue 1, 2010, Pages 97-104

  Schutz, Fabio A B ^a   Oh, William K ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant therapy; Chemotherapy; Prostate cancer

Indexed keywords

ANTIANDROGEN; BEVACIZUMAB; BICALUTAMIDE; CYCLOPHOSPHAMIDE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MITOXANTRONE; PLACEBO; PREDNISONE;

ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED SURGERY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; WATCHFUL WAITING;

CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME;

EID: 75249085782     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.11.012     Document Type: Review

References (47)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 59 4 (2009) 225-249
2. Vessella R.L., and Lange P.H. Issues in the assessment of prostate-specific antigen immunoassays. An update. Urol Clin North Am 24 2 (1997) 261-268
3. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 11 (2003) 2163-2172
4. Catalona W.J., and Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160 6 Pt 2 (1998) 2428-2434
5. Walsh P.C., Partin A.W., and Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152 5 Pt 2 (1994) 1831-1836
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 11 (1998) 969-974
7. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 10 (1998) 766-771
8. Labrie F., Cusan L., Gomez J.L., et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 49 Suppl 3A (1997) 56-64
9. Schulman C.C., Debruyne F.M., Forster G., et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38 6 (2000) 706-713
10. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 1 (2002) 112-116
11. Witjes W.P., Schulman C.C., and Debruyne F.M. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 49 Suppl 3A (1997) 65-69
12. Selli C., Montironi R., Bono A., et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 55 7 (2002) 508-513
13. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166 2 (2001) 506-507 [discussion: 500-6]
14. Klotz L., Gleave M., and Goldenberg S.L. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol 4 3 (2000) 233-237 [discussion: 239]
15. Scolieri M.J., Altman A., and Resnick M.I. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?. J Urol 164 5 (2000) 1465-1472
16. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 124 5 (1967) 1011-1017
17. Myers R.P., Larson-Keller J.J., Bergstralh E.J., et al. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol 147 3 Pt 2 (1992) 910-915
18. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 24 (1999) 1781-1788
19. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 6 (2006) 472-479
20. Siddiqui S.A., Boorjian S.A., Inman B., et al. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 179 5 (2008) 1830-1837 [discussion: 1837]
21. McLeod D.G., Iversen P., See W.A., et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 2 (2006) 247-254
22. McLeod D.G., See W.A., Klimberg I., et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 176 1 (2006) 75-80
23. Iversen P., Johansson J.E., Lodding P., et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172 5 Pt 1 (2004) 1871-1876
24. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 5 (2005) 1285-1290
25. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 9327 (2002) 103-106
26. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 7 (2004) 821-827
27. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 15 (2008) 2497-2504
28. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360 24 (2009) 2516-2527
29. Souhami L., Bae K., Pilepich M., et al. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 27 13 (2009) 2137-2143
30. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 6 (1996) 1756-1764
31. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
32. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 15 (2004) 1502-1512
33. Dreicer R., Magi-Galluzzi C., Zhou M., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 6 (2004) 1138-1142
34. Febbo P.G., Richie J.P., George D.J., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 14 (2005) 5233-5240
35. Prayer-Galetti T., Sacco E., Pagano F., et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100 2 (2007) 274-280
36. Chi K.N., Chin J.L., Winquist E., et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 180 2 (2008) 565-570 [discussion: 570]
37. Oh W.K., Febbo P.G., Richie J.P., et al. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol 27 (2009) 15s (Suppl; abstr 5060)
38. Available at:. www.clinicaltrials.gov Accessed September 10, 2009
39. Schmidt J.D., Gibbons R.P., Murphy G.P., et al. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 29 4 (1996) 425-433
40. Wang J., Halford S., Rigg A., et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 86 6 (2000) 675-680
41. Flaig T.W., Tangen C.M., Hussain M.H., et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26 9 (2008) 1532-1536
42. Kasibhatla M., Peterson B., and Anscher M.S. What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?. Prostate Cancer Prostatic Dis 8 2 (2005) 167-173
43. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 9485 (2005) 572-578
44. Van der Kwast T.H., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25 27 (2007) 4178-4186
45. Van Cangh P.J., Richard F., Lorge F., et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol 159 1 (1998) 164-166
46. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181 3 (2009) 956-962
47. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 15 (2007) 2035-2041